SCHEMBL16305641

SCHEMBL16305641

CC(C)(C)OC(=O)CCNC(=O)[C@H](Cc1ccc(-c2ncc(Br)cn2)cc1)NC(=O)c1ccc(C(C)(C)C)cc1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 2/20 0.46
▸ CTSS P25774 4/20 0.43
▸ CTSK P43235 4/20 0.43
▸ KIFC1 Q9BW19 7/20 0.42
▸ ADCY6 O43306 2/20 0.42
▸ ADCY3 O60266 2/20 0.42
▸ ADCY9 O60503 2/20 0.42
▸ ADCY5 O95622 2/20 0.42
▸ ADCY8 P40145 2/20 0.42
▸ GCGR P47871 2/20 0.42
▸ ADCY7 P51828 2/20 0.42
▸ ADCY2 Q08462 2/20 0.42
▸ ADCY1 Q08828 2/20 0.42
▸ ADCY4 Q8NFM4 2/20 0.42
▸ CTSB P07858 3/20 0.41
▸ CTSL P07711 2/20 0.41
▸ KMT2A Q03164 1/20 0.39
▸ PLG P00747 1/20 0.39
▸ KLKB1 P03952 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22384053 1.00 L3MBTL1 (0.46) L3MBTL1CTSSCTSKKIFC1ADCY6
SCHEMBL22384060 0.93 L3MBTL1 (0.45) L3MBTL1CTSSCTSKKIFC1CTSB
SCHEMBL16295659 0.91 L3MBTL1 (0.48) L3MBTL1CTSSCTSKKIFC1ADCY6
SCHEMBL16295661 0.91 L3MBTL1 (0.48) L3MBTL1CTSSCTSKKIFC1ADCY6
SCHEMBL16305638 0.90 L3MBTL1 (0.46) L3MBTL1CTSSCTSKKIFC1ADCY6
SCHEMBL16294369 0.89 GCGR (0.52) L3MBTL1CTSSCTSKADCY6ADCY3
SCHEMBL16294368 0.89 GCGR (0.52) L3MBTL1CTSSCTSKADCY6ADCY3
SCHEMBL16375227 0.88 L3MBTL1 (0.43) L3MBTL1CTSSCTSKKIFC1ADCY6
SCHEMBL22756131 0.87 CTSS (0.42) L3MBTL1CTSSCTSKADCY6ADCY3
SCHEMBL15037039 0.86 MAPT (0.46) KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3008056-B1 NOVEL GLP-1 RECEPTOR MODULATORS CELGENE INT II SARL (CH) 2020-12-09 — — EP disclosed
EP-3230276-B1 GLP-1 RECEPTOR MODULATORS CELGENE INT II SARL (CH) 2020-09-02 — — EP disclosed
US-10259823-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2019-04-16 — — US disclosed
US-10034886-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2018-07-31 — — US disclosed
US-10034886-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2018-07-31 — — US disclosed
US-20180021346-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2018-01-25 — — US disclosed
US-20180021346-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2018-01-25 — — US disclosed
US-20170313717-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2017-11-02 — — US disclosed
US-20170313717-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2017-11-02 — — US disclosed
US-9795613-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2017-10-24 — — US disclosed
US-9795613-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2017-10-24 — — US disclosed
US-9598430-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2017-03-21 — — US disclosed
US-20160228450-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2016-08-11 — — US disclosed
US-20160228450-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2016-08-11 — — US disclosed
US-20160214993-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2016-07-28 — — US disclosed
US-20160214993-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2016-07-28 — — US disclosed
WO-2016094729-A1 GLP-1 RECEPTOR MODULATORS CELGENE INTERNATIONAL II SARL (CH) 2016-06-16 — — WO disclosed
US-20150011527-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2015-01-08 — — US disclosed
US-20150011527-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2015-01-08 — — US disclosed
WO-2014201172-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS, INC. (US) 2014-12-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160228450-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R L3MBTL1 771/4885CTSS 3233/4885CTSK 3229/4885
US-20170313717-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R L3MBTL1 771/4885CTSS 3233/4885CTSK 3229/4885
US-20160214993-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R L3MBTL1 771/4885CTSS 3233/4885CTSK 3229/4885
US-20180021346-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R L3MBTL1 771/4885CTSS 3233/4885CTSK 3229/4885
US-10034886-B2 GLP-1 receptor modulators GLP1R, GIPR, GCGR L3MBTL1 579/4885CTSS 3308/4885CTSK 3459/4885
US-10259823-B2 GLP-1 receptor modulators GLP1R, GIPR, GCGR L3MBTL1 579/4885CTSS 3308/4885CTSK 3459/4885
US-20150011527-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R L3MBTL1 771/4885CTSS 3233/4885CTSK 3229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback